Remove Drug Delivery Remove Drugs Remove Pharma Companies Remove Reagent
article thumbnail

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

Addressing this need in the market has allowed us penetration to work with 75% of the top twenty pharma companies. Equally, the controlled chemistry of Optimer offers the ability for precise aptamer-drug ratios, with conjugation at specific sites on the molecule to simplify therapeutic manufacture.

article thumbnail

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

Xtalks spoke with WeiQi Lin, MD, PhD, executive vice president, research & development, and principal scientist at DURECT Corporation — a company focused on developing drugs and drug delivery methods in therapeutic areas with significant unmet need — about her transition from academia to industry. Key Moments.